Since the start of the pandemic, fear of drug shortages have been top of mind for companies that source active pharmaceutical ingredients from China. A recent FiercePharma article noted that India, the world’s largest maker of generic drugs, is investing in alternatives to Chinese APIs. The Indian government is establishing a $1.3B fund to produce more APIs domestically. The fund will cover infrastructure and financial incentives for up to 20% of incremental sales value over a period of eight years.
Quick Hits: India Weans Itself off Chinese APIs
India is investing $1.3B to decrease its dependence on Chinese APIs amid supply concerns related to the coronavirus outbreak.
Mar 27, 2020
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
